0QFK Stock Overview
A biotechnology company, focuses on research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.57 |
| 52 Week High | €0.83 |
| 52 Week Low | €0.49 |
| Beta | 1.12 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -69.52% |
| 5 Year Change | -93.01% |
| Change since IPO | -98.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QFK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 2.1% |
| 1Y | n/a | -14.2% | 1.8% |
Return vs Industry: Insufficient data to determine how 0QFK performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0QFK performed against the UK Market.
Price Volatility
| 0QFK volatility | |
|---|---|
| 0QFK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0QFK's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QFK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 18 | Matt Kane | www.celyad.com |
Celyad Oncology SA, a biotechnology company, focuses on research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells.
Celyad Oncology SA Fundamentals Summary
| 0QFK fundamental statistics | |
|---|---|
| Market cap | €18.56m |
| Earnings (TTM) | -€5.82m |
| Revenue (TTM) | €186.00k |
Is 0QFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QFK income statement (TTM) | |
|---|---|
| Revenue | €186.00k |
| Cost of Revenue | €12.00k |
| Gross Profit | €174.00k |
| Other Expenses | €6.00m |
| Earnings | -€5.82m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 25, 2025
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 93.55% |
| Net Profit Margin | -3,131.18% |
| Debt/Equity Ratio | 0% |
How did 0QFK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 10:10 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celyad Oncology SA is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| John Savin | Edison Investment Research |
| Edward White | H.C. Wainwright & Co. |